Previous Close | 264.90 |
Open | 264.90 |
Bid | 264.80 x 0 |
Ask | 282.40 x 0 |
Day's Range | 264.90 - 264.90 |
52 Week Range | 185.25 - 290.60 |
Volume | |
Avg. Volume | 10 |
Market Cap | 96.387B |
Beta (5Y Monthly) | 0.25 |
PE Ratio (TTM) | 41.85 |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Swedish Orphan Biovitrum AB (publ) (Sobi®) has successfully completed the inaugural issue of senior unsecured bonds of SEK 3 billion under its newly established MTN programme.
Sobi® today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has issued a positive opinion recommending approval of efanesoctocog alfa, for the treatment and prevention of bleeds and perioperative prophylaxis in haemophilia A. Efanesoctocog alfa is a once-weekly and high-sustained factor VIII replacement therapy for patients of all ages and any disease severity.
Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the first quarter 2024